Home
Luminex Panels
Human
Human GvHD Biomarker 8-Plex Panel

Human GvHD Biomarker 8-Plex Panel

Q: Which biomarkers are most important for GvHD risk stratification?

ST2 and REG3α are the best-validated individual biomarkers. Published multicenter data (Özbek et al. 2022) demonstrated that their combination achieves AUC=0.79 for predicting 6-month non-relapse mortality.

Q: At which time points should I collect samples for GvHD biomarker monitoring?

Published studies typically collect samples at pre-transplant, Day 0, Day +7, +14, +21, +28, +56, and +100. Wen et al. (2022) reported that sST2 elevation at Day +7 preceded clinical GvHD onset.

Q: Why is IL-6 included if published studies show limited predictive value?

While IL-6 has limited standalone predictive value for 6-month NRM, it remains a useful marker for acute systemic inflammation during the peri-transplant period, providing context for other biomarker readings.

Q: What are the expected concentration ranges for ST2 and REG3α?

ST2 and REG3α concentrations vary widely between subjects and over time. Baseline levels are typically low, with significant elevations observed at GvHD onset. The broad 4-5 log dynamic range accommodates both.

Q: Can this panel distinguish between skin, GI, and liver GvHD?

Organ-specific biomarker signatures have been identified: Elafin is associated with skin GvHD, ST2 + REG3α with GI GvHD, and HGF with liver involvement. Multiplex profiling assesses all three from a single sample.

Q: How do GI tissue damage biomarkers differ from systemic inflammation markers?

GI tissue damage biomarkers (ST2, REG3α) reflect direct end-organ injury and are better predictors of long-term outcomes including 6-month NRM, while systemic inflammation markers (IL-6, TNFR1) have limited independent value.

Simultaneous quantification of 8 validated graft-versus-host disease biomarkers in a single well using Luminex xMAP technology. Designed for acute GvHD risk stratification, post-transplant longitudinal monitoring, and organ-specific biomarker research.

8 TargetsHuman25 μL SampleSub-pg/mL Sensitivity

Request a Quote View Analytes

Graft-versus-host disease (GvHD) is the most serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), affecting 30-70% of transplant recipients. Acute GvHD involves immune-mediated damage to the skin, liver, and gastrointestinal tract driven by donor T cell activation against host tissues. Reliable, non-invasive biomarkers are critical for early GvHD detection and risk stratification, as clinical symptoms often overlap with infection and drug toxicity.

Creative Proteomics offers the Human GvHD Biomarker 8-Plex Panel based on the Luminex xMAP platform for simultaneous quantification of 8 key biomarkers validated in multicenter clinical studies for acute GvHD prediction. This panel covers GI tissue damage markers (ST2 and REG3α), systemic inflammation markers (TNFR1, IL-6), organ-specific markers (Elafin for skin, IL-8 for endothelial activation), and tissue repair and activation markers (HGF, IL-2Rα).

Published data from Özbek et al. (2022) demonstrated that ST2 and REG3α outperform pure systemic inflammation markers for GvHD risk stratification in a multicenter validation cohort of 730 patients. The panel is validated for serum and plasma, compatible with MAGPIX, Luminex 200, and FLEXMAP 3D systems. Compared to ELISA requiring 8 separate wells, this single assay delivers data for all 8 GvHD biomarkers from just 25 μL of sample.

Panel Specifications

TechnologyLuminex xMAP

Panel Size8-plex

SpeciesHuman

Sample Volume25 μL

SensitivitySub-pg/mL

Dynamic Range4-5 logs

Assay Time3-4 hours

Complete Analyte List (8 GvHD Biomarkers)

The Human GvHD Biomarker 8-Plex Panel detects the following targets with validated sensitivity and specificity. Each analyte has a well-established role in GvHD pathophysiology, supported by multicenter clinical studies.

Target	Alternative Name	Role in GvHD
ST2	IL-1RL1, sST2	GI tissue damage marker; strongest individual predictor of acute GvHD severity and 6-month non-relapse mortality
REG3α	Pancreatitis-associated protein	Paneth cell protein; GI crypt damage marker; combined with ST2 achieves AUC=0.79 for GvHD risk stratification
TNFR1	TNFRSF1A, sTNF-RI	Soluble TNF receptor; systemic inflammation marker reflecting TNF-α activity
IL-6	Interleukin-6	Acute phase cytokine; elevated in severe GvHD
IL-8	CXCL8	Neutrophil chemotaxis; endothelial activation marker
HGF	Hepatocyte growth factor	Tissue repair and regeneration marker
Elafin	PI3, SKALP	Skin-specific biomarker; elevated in cutaneous GvHD
IL-2Rα	CD25, sCD25	T cell activation marker; elevated during GvHD onset

Technical Specifications

Validated performance parameters for the Human GvHD Biomarker 8-Plex Panel.

Platform and Assay

PlatformLuminex xMAP (MAGPIX / Luminex 200 / FLEXMAP 3D)

Panel Size8-plex

SpeciesHuman

Sample TypesSerum, EDTA/Heparin Plasma

Sample Volume25 μL per well

Assay Time3-4 hours

Performance Metrics

SensitivitySub-pg/mL (varies by analyte)

Dynamic Range4-5 logs

Intra-Assay CV<10%

Inter-Assay CV<15%

Spike Recovery80-120%

Standard Curve5PL fit, R² > 0.98

Luminex vs ELISA for GvHD Biomarker Analysis

Traditional ELISA requires 8 separate assays to cover the biomarkers in this panel. Our Luminex multiplex panel quantifies all 8 GvHD biomarkers simultaneously in a single well, preserving precious clinical specimens.

Parameter	Luminex 8-Plex Panel	Traditional ELISA (8 assays)
Targets per Well	8	1
Wells Required	1	8
Sample Volume	25 μL	200 μL
Assay Time	3-4 hours	24-32 hours
Dynamic Range	4-5 logs	1-2 logs
Data Points per Sample	8	1
Re-dilution Required	Rarely (broad range)	Often (narrow range)
Cost per Target	Lower (shared reagents)	Higher (separate kits)

For GvHD studies where blood samples are collected at serial time points (pre-transplant, day 0, day +7, day +14, day +28), multiplex analysis from a single 25 μL sample is essential for preserving precious clinical specimens while capturing the complete biomarker profile.

Sample Requirements for GvHD Biomarker Luminex Assays

Proper sample collection and handling are essential for reliable GvHD biomarker measurements. Consistent time point collection relative to transplant date is critical for longitudinal studies.

Recommended Sample Types

Serum25 μL, collect in SST tubes, no hemolysis

EDTA/Heparin Plasma25 μL, clear, no fibrin

Minimum Project SizeOne 96-well plate; smaller batches accepted with surcharge

ReplicatesDuplicate recommended

Handling and Shipping Notes

Sample Storage-80°C; avoid repeated freeze-thaw cycles

ShippingDry ice or wet ice

Transplant Study NoteStandardize collection time points relative to transplant date. Typical schedule: pre-HSCT, Day 0, Day +7, Day +14, Day +21, Day +28, Day +56, Day +100

How This Panel Works

The GvHD Biomarker 8-Plex Panel is designed to support longitudinal transplant studies with minimal sample volume requirements. Choose the right sampling strategy based on your research objectives.

GvHD Biomarker Panel

Simultaneously quantifies 8 key GvHD biomarkers covering GI tissue damage (ST2, REG3α), systemic inflammation (TNFR1, IL-6), organ-specific markers (Elafin for skin, IL-8 for endothelium), and tissue repair/activation (HGF, IL-2Rα). 25 μL per well.

Choose this for: comprehensive GvHD biomarker profiling

Serial

Longitudinal Monitoring Schedule

Supports serial sampling at standard transplant time points: pre-HSCT, Day 0, Day +7, +14, +21, +28, +56, and +100. Published studies show sST2 elevation as early as Day +7 precedes clinical GvHD onset. 25 μL per time point minimizes blood draw burden.

Choose this for: post-transplant trajectory studies

Custom

Flexible Collection Schedule

Customize your collection schedule based on study design. Additional collection windows at GvHD onset, steroid response assessment, and follow-up can be incorporated. Contact us for protocol optimization.

Choose this for: customized study protocols

Planning a GvHD biomarker study? Contact us with your study design and sample collection schedule. We will recommend the optimal panel configuration and provide guidance on standardized collection time points.

GvHD Biomarker Panel Research Applications

The Human GvHD Biomarker 8-Plex Panel supports research across acute GvHD risk stratification, post-transplant monitoring, organ-specific biomarker investigation, and transplant biomarker discovery.

Acute GvHD Risk Stratification

Quantify ST2 and REG3α at GvHD onset to classify patients into high-risk and low-risk groups. The Ann Arbor (MAGIC) algorithm uses ST2 + REG3α concentrations, validated in multicenter studies with AUC=0.79 for predicting 6-month non-relapse mortality.

Post-Transplant Longitudinal Monitoring

Measure biomarkers at serial time points (Day +7, +14, +21, +28) to track biomarker trajectories before clinical GvHD onset. Wen et al. (2022) reported that sST2 elevation at Day +7 preceded clinical GvHD diagnosis in pediatric patients.

Organ-Specific GvHD Research

Distinguish skin GvHD (Elafin elevation), GI GvHD (ST2 + REG3α), and systemic GvHD (TNFR1 + IL-6) using organ-specific biomarker signatures. Multiplex profiling enables simultaneous assessment of all three organ systems from a single sample.

Steroid Response Prediction

Biomarker levels at GvHD onset correlate with likelihood of response to first-line corticosteroid therapy. High ST2 + REG3α identifies patients who may benefit from early escalation to second-line therapy, as demonstrated in multicenter validation studies.

Transplant Biomarker Discovery

Eight-analyte multiplex enables screening of multiple GvHD-associated biomarkers from minimal sample volume. Supports biomarker discovery in prospective transplant cohorts with comprehensive coverage of GI damage, inflammation, and organ-specific markers.

Deliverables and Quality Metrics

Every Luminex multiplex assay includes a comprehensive data package with full quality control documentation for all 8 GvHD biomarkers.

Data Package

Raw fluorescence intensities (FI) for all bead regions (.csv)
Calculated concentrations (pg/mL) for each of the 8 biomarkers
5PL standard curves (R² > 0.98)
Full QC report (.xlsx)

Quality Control

Standard curve: 8-point dilution series, 5PL fit, R² > 0.98
Intra-assay CV < 10%
Inter-assay CV < 15%
Spike recovery: 80-120%

Assay Performance

Duplicate sample measurements
Method summary with reagent lot numbers
Detection limits per analyte
Platform: Luminex xMAP (MAGPIX, Luminex 200, FLEXMAP 3D)

Case Study: GvHD Biomarker Validation in Multicenter Cohort (Özbek et al. 2022)

Özbek U, et al. validated GvHD biomarkers in a prospective multicenter study of 730 patients across 19 transplant centers, demonstrating that ST2 + REG3α is the best-validated two-biomarker combination for GvHD risk stratification.

Özbek U, et al. (2022) conducted a prospective multicenter study using a PRoBE (Prospective-specimen collection, Retrospective-Blinded-Evaluation) design with separate training (n=352) and validation (n=378) cohorts across 19 transplant centers. The study compared multiple biomarker algorithms including TNFR1, TIM3, IL-6, ST2, and REG3α for predicting 6-month non-relapse mortality (NRM). Assays were performed using ELISA for individual markers and Luminex-compatible multiplex configurations.

ST2 + REG3α Algorithm Performance (Validation Cohort)

Metric	Value
AUC	0.79
Sensitivity	75.0%
Specificity	76.1%
PPV	33.3%
NPV	95.0%

Clinical Outcomes by Risk Group

Outcome	Low Risk	High Risk
Response to Steroids	76%	51%
6-Month NRM	6%	34%
6-Month Survival	90%	60%

Key Findings

ST2 + REG3α was the best-performing 2-biomarker combination across all tested panels for predicting 6-month non-relapse mortality.
Algorithms containing only systemic inflammation biomarkers (TNFR1 + TIM3, AUC=0.57) predicted short-term steroid response but NOT 6-month NRM, demonstrating limited standalone predictive value.
At least one GI tissue damage biomarker (ST2 or REG3α) was required to predict long-term outcomes, highlighting the critical role of organ-specific damage markers in GvHD risk stratification.
IL-6 failed to meet statistical criteria as a standalone predictor for 6-month NRM, confirming that pure inflammation markers have limited prognostic utility for long-term transplant outcomes.

Implications for GvHD Biomarker Research

ST2 + REG3α is the current benchmark: A panel that includes both GI damage markers provides the best-validated risk stratification for acute GvHD. The 8-plex panel includes both as core analytes.
GI biomarkers outperform systemic markers: Pure inflammation markers (IL-6, TNFR1) have limited standalone predictive value. An effective GvHD panel must include tissue-specific damage markers alongside systemic inflammation markers for comprehensive profiling.
Longitudinal design is essential: Biomarker trajectories from pre-transplant through Day +100 provide more information than single time-point measurements. The 25 μL sample requirement of Luminex multiplex enables serial sampling without excessive blood draw burden.

Source: Özbek U, et al. Blood Adv. 2022;6(12):3707-3715. DOI: 10.1182/bloodadvances.2022007296 · PMC9631548.

Related Panels

Explore other Luminex multiplex panels available for cytokine, inflammation, and transplant biomarker research.

Human Cell Therapy Cytokine Panel

Targets: IL-6, IFN-γ, GM-CSF, IL-10, IL-2, IP-10
Platform: Luminex
Plex: 20/25-Plex

View Details

Human Inflammation Panel

Targets: IL-6, TNF-α, IL-1β, IP-10, IFN-γ
Platform: Luminex
Plex: 20 to 48-Plex

View Details

Human Immune Checkpoint 37-Plex Panel

Targets: PD-1, PD-L1, CTLA-4, TIM-3, LAG-3
Platform: Luminex
Plex: 37-Plex

View Details

Human TNF Family 15-Plex Panel

Targets: TNF-α, FasL, TRAIL, BAFF, APRIL, TWEAK
Platform: Luminex
Plex: 15-Plex

View Details

Human Chemokine Panel

Targets: CXC, CC, C, CX3C subfamilies
Platform: Luminex
Plex: Multiplex

View Details

Human Growth Factor Panel

Targets: EGF, FGF, VEGF, HGF, PDGF
Platform: Luminex
Plex: 11-Plex

View Details

Human Complement Factor Panel

Targets: C1q, C3, C4, Factor B, Properdin
Platform: Luminex
Plex: 7 to 8-Plex

View Details

Human Cytokine Luminex Multiplex Panels

Targets: Custom cytokine selection
Platform: Luminex
Plex: 15 to 96-Plex

View Details

Human Cancer Biomarker Panel

Targets: Oncology cytokines, growth factors
Platform: Luminex
Plex: Multiplex

View Details

MSD Immuno-Oncology Panel

Targets: Immune checkpoint, cytokines
Platform: MSD ECL
Focus: fg/mL detection

View Details

← All Human PanelsBrowse species overview

Supporting Publications for GvHD Biomarker Multiplex Assays

Selected references utilizing GvHD biomarker assays for risk stratification and post-transplant monitoring in multicenter clinical studies.

MULTICENTER VALIDATION

Özbek U, et al. (2022) Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Adv. 6(12):3707-3715.

DOI: 10.1182/bloodadvances.2022007296

EXTERNAL VALIDATION

Robin M, et al. (2022) Prospective external validation of biomarkers to predict acute graft-versus-host disease severity. Blood Adv. 6(16):4763-4772.

DOI: 10.1182/bloodadvances.2022007477

PEDIATRIC GvHD

Wen X, et al. (2022) Correlation of the level of plasma biomarkers with acute GVHD in children after allo-HSCT. Chin J Tissue Eng Res. 26(31):5032-5039.

Open Access (Chinese)

Customization available: Select specific GvHD biomarkers, expand plex capacity, or optimize for unusual sample matrices. Contact us for a custom quote

Frequently Asked Questions About GvHD Biomarker 8-Plex Panel

Common questions about our human GvHD biomarker Luminex multiplex panel service.

Which biomarkers are most important for GvHD risk stratification?

ST2 and REG3α are the best-validated individual biomarkers. Published multicenter data (Özbek et al. 2022) demonstrated that their combination achieves AUC=0.79 for predicting 6-month non-relapse mortality. The 8-plex panel includes both, plus additional organ-specific markers (Elafin for skin GvHD, HGF for tissue repair, IL-8 for endothelial activation) and systemic inflammation markers (TNFR1, IL-6) for comprehensive profiling.

At which time points should I collect samples for GvHD biomarker monitoring?

Published studies typically collect samples at pre-transplant, Day 0, Day +7, +14, +21, +28, +56, and +100. Wen et al. (2022) reported that sST2 elevation at Day +7 preceded clinical GvHD onset in pediatric patients. We recommend developing a standardized collection schedule with consistent time points relative to the transplant date for optimal longitudinal data quality.

Why is IL-6 included if published studies show limited predictive value?

While IL-6 has limited standalone predictive value for 6-month NRM, it remains a clinically useful marker for acute systemic inflammation during the peri-transplant period. Including IL-6 in the panel provides context for other biomarker readings and supports comprehensive immune monitoring throughout the transplant course.

What are the expected concentration ranges for ST2 and REG3α?

ST2 and REG3α concentrations vary widely between patients and over time. Baseline (pre-transplant) levels are typically low, with significant elevations observed at GvHD onset. The broad dynamic range of Luminex (4-5 logs) accommodates both baseline and peak levels without requiring re-dilution, making it ideal for longitudinal studies with wide concentration ranges.

Can this panel distinguish between skin, GI, and liver GvHD?

Organ-specific biomarker signatures have been identified in published studies: Elafin is associated with skin GvHD, ST2 + REG3α with GI GvHD, and HGF with liver involvement. Multiplex profiling from a single sample enables simultaneous assessment of all three organ systems, supporting organ-specific GvHD research without requiring separate assays for each biomarker.

How do GI tissue damage biomarkers differ from systemic inflammation markers?

GI tissue damage biomarkers (ST2, REG3α) reflect direct end-organ injury to the gastrointestinal tract and are better predictors of long-term outcomes including 6-month NRM and overall survival. Systemic inflammation markers (IL-6, TNFR1) reflect the broader cytokine response but have limited independent predictive value for GvHD outcomes. The 8-plex panel includes both categories for comprehensive biomarker assessment.

Interested in This Panel?

Contact us to discuss your GvHD biomarker project requirements, panel configuration, and sample collection strategy. We respond within 24 hours.

Request a Quote

For Research Use Only. Not for use in diagnostic or clinical procedures.

Inquiry Basket